home / stock / cdxi / cdxi quote
Last: | $1e-06 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $1e-06 |
High: | $0 |
Low: | $0 |
Volume: | 108 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1e-06 | $0 | $1e-06 | $0 | $0 | 108 | 04-02-2024 |
$1e-06 | $0 | $1e-06 | $0 | $0 | 50 | 01-29-2024 |
$1e-06 | $0 | $1e-06 | $0 | $0 | 1 | 01-03-2024 |
$1e-06 | $1e-06 | $1e-06 | $1e-06 | $1e-06 | 1,878 | 12-27-2023 |
$1e-06 | $0 | $1e-06 | $0 | $0 | 2 | 12-26-2023 |
$1e-06 | $1e-06 | $1e-06 | $1e-06 | $1e-06 | 1,000 | 12-07-2023 |
$0.0002 | $0 | $0.0002 | $0 | $0 | 70 | 10-17-2023 |
$0.0002 | $0 | $0.0002 | $0 | $0 | 1 | 09-18-2023 |
$0.0002 | $0.0002 | $0.0002 | $0.0002 | $0.0002 | 1,095 | 07-04-2023 |
$0.0002 | $0.0002 | $0.0002 | $0.0002 | $0.0002 | 1,095 | 07-03-2023 |
$0.0002 | $0 | $0.0002 | $0 | $0 | 17 | 06-30-2023 |
$0.0002 | $0 | $0.0002 | $0 | $0 | 50 | 06-22-2023 |
$0.0002 | $0.0002 | $0.0002 | $0.0002 | $0.0002 | 260 | 06-05-2023 |
$0.0011 | $0 | $0.0011 | $0 | $0 | 5 | 05-16-2023 |
$0.0011 | $0 | $0.0011 | $0 | $0 | 10 | 05-15-2023 |
$0.0011 | $0.0011 | $0.0011 | $0.0011 | $0.0011 | 180 | 05-01-2023 |
$0.0002 | $0 | $0.0002 | $0 | $0 | 8 | 04-20-2023 |
$0.0002 | $0.0002 | $0.0002 | $0.0002 | $0.0002 | 333 | 04-14-2023 |
$0.0002 | $0 | $0.0002 | $0 | $0 | 8 | 03-02-2023 |
$0.0002 | $0.0011 | $0.0002 | $0.0011 | $0.0002 | 381 | 02-16-2023 |
News, Short Squeeze, Breakout and More Instantly...
Cardax Voluntarily Suspends SEC Reporting Obligations Expected savings to support core business strategies PR Newswire HONOLULU , Aug. 11, 2021 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today the filing of a Form 15 with the U.S. Securities and...
Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing multiple funding opportunities PR Newswire HONOLULU , May 14, 2021 /PRNewswi...
Cardax Reports 2020 Results - Net loss and operating expenses decreased vs. 2019 - ZanthoSyn® revenues decreased vs. 2019 - Company pursuing multiple funding opportunities - CHASE study recruitment suspended due to COVID-19 - COVID-19 clinical trial grant ap...